Rapalogs and mTOR inhibitors as anti-aging therapeutics
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rapamycin and its analogs (so-called ‘rapalogs’) suppress the SASP by inhibiting mTOR and appear to extend healthspan and lifespan in mice105,108,109.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In fact, reviewing the effects of other interventions like rapalogs and sirtuins also shows that they may be impacting many of the similar hallmarks of aging (Lamming et al. 2013, Grabowska et al. 2017).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Lamming et al. 2013
The cited source says what the claim attributes to it.
In the citing paper
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and slowed clinical evaluation of mTOR inhibitors for diseases of aging 26.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SASP inhibitors (senomorphics) can directly or indirectly attenuate the SASP of senescent cells by inhibiting transcription factor nuclear factor (NF)-κB, the JAK-STAT signal transduction pathway, the serine/threonine protein kinase mTOR, mitochondrial complex-1-related or 4-related targets, or other pathways involved in the induction and maintenance of the SASP103–106.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“no senolytic compounds developed to date are able to eliminate all types of senescent cells; further they retain a low level of toxicity to young normal cells (Lamming et al., 2013).”
From Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion (2019) · cites this paper as Lamming et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“the autophagy-initiating kinase ULK1 (46).”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“This effect was first observed in certain cultured cell lines (73), and we have recently shown that it also occurs in vivo in multiple tissues including liver, muscle, and adipose (see Figure 2).”
BackgroundSelf-citationLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170 · cited 1×
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Chronic, low-grade inflammation is a feature of aging, and almost every chronic disease has an inflammatory component (71).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 2×
“Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.”
Background
Cited by
Mechanism and medical implications of mammalian autophagy
Dikic, I., & Elazar, Z. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0003-4 · Cited by 2,771
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Mills, K. F., Yoshida, S., Stein, L. R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, M. E., Apte, R. S., Uchida, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.013 · Cited by 930
“Ce aging healthy and prevent expensive age-associated health problems, efforts to develop effective, affordable, anti-aging interventions have recently been intensified, leading to some promising compounds, such as metformin, rapamycin, and SIRT1 activators (Barzilai et al., 2016; Hubbard and Sinclair, 2014; Lamming e…”
Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
Wang, S., Tsun, Z.-Y., Wolfson, R. L., Shen, K., Wyant, G. A., Plovanich, M. E., Yuan, E. D., Jones, T. D., Chantranupong, L., Comb, W., et al. (2015) · Science · doi:10.1126/science.1257132 · Cited by 824
“Lastly, a selective mTORC1 pathway inhibitor may have better clinical benefits than rapamycin, which in long-term use inhibits both mTORC1 and mTORC2 (37).”
BackgroundSelf-citationBenefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
Identification of HSP90 inhibitors as a novel class of senolytics
Fuhrmann-Stroissnigg, H., Ling, Y. Y., Zhao, J., McGowan, S. J., Zhu, Y., Brooks, R. W., Grassi, D., Gregg, S. Q., Stripay, J. L., Dorronsoro, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00314-z · Cited by 701
Targeting cellular senescence with senotherapeutics: senolytics and senomorphics
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023) · The FEBS Journal · doi:10.1111/febs.16350 · Cited by 621
Interventions to slow aging in humans: are we ready?
Longo, V. D., Antebi, A., Bartke, A., Barzilai, N., Brown‐Borg, H. M., Caruso, C., Curiel, T. J., Cabo, R., Franceschi, C., Gems, D., et al. (2015) · Aging Cell · doi:10.1111/acel.12338 · Cited by 592
“Rapamycin has been studied for decades, tested in hundreds of clinical trials, and approved for use in several clinical conditions, including kidney cancers (Lamming et al., 2013; Kennedy & Pennypacker, 2014).”
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
Zhong, Z., Sanchez-Lopez, E., & Karin, M. (2016) · Cell · doi:10.1016/j.cell.2016.05.051 · Cited by 576
“Many of these agents exhibit anti-aging and anti-tumor properties (Bhullar and Hubbard, 2015; Foretz et al., 2014; Lamming et al., 2013; Morselli et al., 2010).”
Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases
Barnes, P. J., Baker, J., & Donnelly, L. E. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1975tr · Cited by 555
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
“will retain the beneficial effects of rapamycin and is likely to result in reduced side effects (Lamming et al., 2013).”
Self-citationLeeman, D. S., Hebestreit, K., Ruetz, T., Webb, A. E., McKay, A., Pollina, E. A., Dulken, B. W., Zhao, X., Yeo, R. W., Ho, T. T., et al. (2018) · Science · doi:10.1126/science.aag3048 · Cited by 528
The aging lung: Physiology, disease, and immunity
Schneider, J. L., Rowe, J. H., Garcia-de-Alba, C., Kim, C. F., Sharpe, A. H., & Haigis, M. C. (2021) · Cell · doi:10.1016/j.cell.2021.03.005 · Cited by 500
“mTOR inhibition by rapamycin and its analogs derepress autophagy and extend bothmean andmaximum lifespan in a variety of model organisms including mammals (Lamming et al., 2013).”
AMPK at the Nexus of Energetics and Aging
Burkewitz, K., Zhang, Y., & Mair, W. B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.002 · Cited by 483
“Long-term DR also increases AMPKa Thr172 phosphorylation in mouse heart (Edwards et al., 2010) and skeletal muscle (Palacios et al., 2009).”
BackgroundThe molecular targets of resveratrol
Kulkarni, S. S., & Cantó, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.005 · Cited by 477
“mTOR complexes 1 and 2 (mTORC1 and mTORC2), the mTOR kinase plays a key role in several pathways involved in cancer and metabolic diseases [121].”
BackgroundInfluentialTaurine deficiency as a driver of aging
Singh, P., Gollapalli, K., Mangiola, S., Schranner, D., Yusuf, M. A., Chamoli, M., Shi, S. L., Lopes Bastos, B., Nair, T., Riermeier, A., et al. (2023) · Science · doi:10.1126/science.abn9257 · Cited by 435
Autophagy and the cell biology of age-related disease
Leidal, A. M., Levine, B., & Debnath, J. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0235-8 · Cited by 424
Palmieri, M., Pal, R., Nelvagal, H. R., Lotfi, P., Stinnett, G. R., Seymour, M. L., Chaudhury, A., Bajaj, L., Bondar, V. V., Bremner, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms14338 · Cited by 383
“…prion disease 59 . mTORC1, however, acts as a central regulatory hub controlling anabolic pathways such as cell growth by modulating the synthesis of proteins, lipids and nucleotides 60 , and long-term mTORC1 inhibition results in induction of immunosuppression and impaired wound healing 3,61 .”
Autophagy in liver diseases: Time for translation?
Allaire, M., Rautou, P.-E., Codogno, P., & Lotersztajn, S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.026 · Cited by 378
Targeting the biology of aging with mTOR inhibitors
Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and have slowed clinical evaluation of mTOR inhibitors for diseases of aging 26 .”
Self-citationStrong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., Fernandez, E., Flurkey, K., Hamilton, K. L., Lamming, D. W., et al. (2016) · Aging Cell · doi:10.1111/acel.12496 · Cited by 362
“…to test the combination of Met and Rapa was based on the idea that the disturbances in glucose homeostasis induced by Rapa might limit its benefits on lifespan (Lamming et al., 2013) and that Met, by increasing insulin sensitivity, might therefore compensate for potentially harmful side effects.”
BackgroundSelf-citationA Central Role for mTOR in Lipid Homeostasis
Lamming, D. W., & Sabatini, D. M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.002 · Cited by 361
“The past several years have seen an explosion of interest in the mTOR signaling pathway, spurred in large part by the finding that inhibition of mTORC1 signaling can significantly increase lifespan and protect from age-related diseases in mouse models (reviewed in (Lamming et al., 2013)).”
Self-citationAutophagy is a critical regulator of memory CD8+ T cell formation
Puleston, D. J., Zhang, H., Powell, T. J., Lipina, E., Sims, S., Panse, I., Watson, A. S., Cerundolo, V., Townsend, A. R., Klenerman, P., et al. (2014) · eLife · doi:10.7554/elife.03706 · Cited by 360
“As mTOR inhibition, such as achieved with rapamycin, is well known for its multiple side effects (Lamming et al., 2013), we confirmed that spermidine induces autophagy in T cells in an mTOR-independent manner.”
BackgroundTargeting senescent cells in translational medicine
Paez‐Ribes, M., González‐Gualda, E., Doherty, G. J., & Muñoz‐Espín, D. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810234 · Cited by 293
“Newer mTOR inhibitors with comparatively advantageous pharmacological properties have been developed and may also target detrimental effects of the SASP (Lamming et al, 2013; Leontieva et al, 2015).”
BackgroundMammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
De Meyer, G. R. Y., Grootaert, M. O. J., Michiels, C. F., Kurdi, A., Schrijvers, D. M., & Martinet, W. (2015) · Circulation Research · doi:10.1161/circresaha.116.303804 · Cited by 287
“Later, however, it was found to have potent immunosuppressive effects in mammals so that it could be used in autoimmune disorders and after organ transplantation.(77,78) Because rapamycin is a potent inhibitor of mTOR complex 1 (mTORC1), rapamycin is also useful as a proliferation inhibitor to prevent SMC migration an…”
BackgroundCurrent treatment strategies for inhibiting mTOR in cancer
Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 275
Metformin as an Anticancer Agent
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., & Vancurova, I. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.006 · Cited by 274
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
“Use in PHTS Three individuals with PTEN mutations treated with mTOR inhibitors exist in the literature (Table VII).”
BackgroundInfluentialSenescence in COPD and Its Comorbidities
Barnes, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034314 · Cited by 266
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Liu, J., Wang, Z., Tong, B. C.-K., Song, J., Lu, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030728 · Cited by 263
“Additionally, mTOR inhibitors, such as rapamycin, may have some side effects in clinical trials [114,115].”
BackgroundPalmieri, M., Pal, R., Nelvagal, H. R., Lotfi, P., Stinnett, G. R., Seymour, M. L., Chaudhury, A., Bajaj, L., Bondar, V. V., Bremner, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15793 · Cited by 261
The crucial impact of lysosomes in aging and longevity
Carmona-Gutierrez, D., Hughes, A. L., Madeo, F., & Ruckenstuhl, C. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.009 · Cited by 244
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
Arriola Apelo, S. I., & Lamming, D. W. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw090 · Cited by 239
“Rapalogs include the FDA-approved everolimus and temsirolimus plus ridaforolimus, zotarolimus, and 32-deoxo-rapamycin (101).”
BackgroundSelf-citationFontaine, D. A., & Davis, D. B. (2016) · Diabetes · doi:10.2337/db15-0982 · Cited by 234
“Raptor is a key protein in the regulation of the frequently studied mammalian target of rapamycin complex 1 (mTORC1) signaling pathways (19).”
BackgroundAutophagy and aging: Maintaining the proteome through exercise and caloric restriction
Escobar, K. A., Cole, N. H., Mermier, C. M., & VanDusseldorp, T. A. (2019) · Aging Cell · doi:10.1111/acel.12876 · Cited by 227
TOR signaling in plants: conservation and innovation
Shi, L., Wu, Y., & Sheen, J. (2018) · Development · doi:10.1242/dev.160887 · Cited by 226
The Ras-Erk-ETS-signaling pathway is a drug target for longevity
Slack, C., Alic, N., Foley, A., Cabecinha, M., Hoddinott, M. P., & Partridge, L. (2015) · Cell · doi:10.1016/j.cell.2015.06.023 · Cited by 224
“Rapamycin not only increases lifespan in multiple organisms, including mammals, but also improves several indices of function during aging (Ehninger et al., 2014; Lamming et al., 2013).”
BackgroundPeng, M., Yin, N., & Li, M. O. (2014) · Cell · doi:10.1016/j.cell.2014.08.038 · Cited by 220
mTOR pathway activation drives lung cell senescence and emphysema
Houssaini, A., Breau, M., Kebe, K., Abid, S., Marcos, E., Lipskaia, L., Rideau, D., Parpaleix, A., Huang, J., Amsellem, V., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93203 · Cited by 220
“Several lines of evidence also indicate that mTOR is a major cell senescence pathway (15).”
Xu, H., Aldrich, M. C., Chen, Q., Liu, H., Peterson, N. B., Dai, Q., Levy, M., Shah, A., Han, X., Ruan, X., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2014-002649 · Cited by 218
“The mechanism by which metformin improves cancer survival either directly (insulin-independent) or indirectly (insulindependent) remains unknown(37,40,55,56) but may be related to mTOR inhibition.(57,58) The broad-based effect on multiple cancers seen in this study suggests a generalized anticancer effect.”
BackgroundZhao, P., Sui, B., Liu, N., Lv, Y., Zheng, C., Lu, Y., Huang, W., Zhou, C., Chen, J., Pang, D., et al. (2017) · Aging Cell · doi:10.1111/acel.12635 · Cited by 212
“RAPA, an immunosuppressant (Lamming et al., 2013), has been shown”
BackgroundInfluentialSenotherapeutics: emerging strategy for healthy aging and age-related disease
Kim, E.-C., & Kim, J.-R. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.293 · Cited by 208
“anti-senescence compounds, such as telomerase activator (45), CRMs (7), caloric restriction diets (8), sirtuin activators (46), mTOR inhibitors (47), antioxidants (48), anti-inflammatory”
BackgroundThe ageing kidney: Molecular mechanisms and clinical implications
Fang, Y., Gong, A. Y., Haller, S. T., Dworkin, L. D., Liu, Z., & Gong, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101151 · Cited by 204
“Genetic or pharmacological inhibition of mTOR signaling has been reported to prolong lifespan of invertebrates (Lamming et al., 2013) and genetically heterogeneous mice (Harrison et al.”
Song, Y., Huang, Z., Liu, X., Pang, Z., Chen, J., Yang, H., Zhang, N., Cao, Z., Liu, M., Cao, J., et al. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.08.002 · Cited by 203
Mechanisms of development of multimorbidity in the elderly
Barnes, P. J. (2015) · European Respiratory Journal · doi:10.1183/09031936.00229714 · Cited by 195
Inhibition of the Mechanistic Target of Rapamycin (mTOR)–Rapamycin and Beyond
Lamming, D. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025924 · Cited by 195
“As we have previously detailed (Lamming et al. 2013), the proposed mechanisms by which rapamycin extends life span include suppression of cancer, inhibition of translation, maintenance of protein quality, and effects on stem cells.”
BackgroundSelf-citationProteostasis in cardiac health and disease
Henning, R. H., & Brundel, B. J. J. M. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.89 · Cited by 193
Mitochondrial Hormesis and Diabetic Complications
Sharma, K. (2015) · Diabetes · doi:10.2337/db14-0874 · Cited by 193
“However, deletion of SOD2 has also been reported to increase autophagy in mouse embryonic fibroblasts (20), which is in contrast to the finding that aging is associated with a reduction in autophagy and an increase in mammalian target of rapamycin (mTOR) (21).”
Therapeutic interventions for aging: the case of cellular senescence
Soto-Gamez, A., & Demaria, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.004 · Cited by 192
mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
Ardestani, A., Lupse, B., Kido, Y., Leibowitz, G., & Maedler, K. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.004 · Cited by 190
“mTORC1signaling hasalsobeen linked to aging, with genetic or pharmacologic inhibition of TOR extending longevity in several eukaryotic organisms (Arriola Apelo and Lamming, 2016; Lamming et al., 2013).”
BackgroundRomero, Y., Bueno, M., Ramirez, R., Álvarez, D., Sembrat, J. C., Goncharova, E. A., Rojas, M., Selman, M., Mora, A. L., & Pardo, A. (2016) · Aging Cell · doi:10.1111/acel.12514 · Cited by 188
“Rapamycin is an allosteric inhibitor of mTORC1 and PP242 is a new drug with potent and selective inhibitory effect on ATP domain of mTOR that suppresses its activity in both complexes (Lamming et al., 2013).”
BackgroundLithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis
Castillo-Quan, J. I., Li, L., Kinghorn, K. J., Ivanov, D. K., Tain, L. S., Slack, C., Kerr, F., Nespital, T., Thornton, J., Hardy, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.041 · Cited by 186
“Genetic and environmental interventions that extend lifespan often induce abnormalities in carbohydrate and lipid metabolism (Barzilai et al., 2012;Wang et al., 2014; Lamming et al., 2013).”
BackgroundComing of age: molecular drivers of aging and therapeutic opportunities
Newgard, C. B., & Sharpless, N. E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68833 · Cited by 184
“(13), argue that further investigation of the connections between sirtuins and aging could well be fruitful.”
BackgroundInfluentialArriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182
“Unfortunately, the potential for serious side effects in humans, including immunosuppression and glucose intolerance, may preclude the long-term prophylactic use of rapamycin as a therapy for age-related diseases (Lamming et al., 2013b).”
BackgroundResultSelf-citationCaccamo, A., De Pinto, V., Messina, A., Branca, C., & Oddo, S. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0777-14.2014 · Cited by 182
“…that reducing the activity of the mammalian target of rapamycin (mTOR) increases lifespan and health-span in several genetically different species (Lamming et al., 2013). mTOR is a ubiquitously expressed protein kinase that plays a key role in regulating protein synthesis and cell growth by…”
BackgroundNakamura, S., & Yoshimori, T. (2018) · PubMed · doi:10.14348/molcells.2018.2333 · Cited by 154
“After that, other groups also confirmed the positive effect of rapamycin on lifespan in mice using different genetic backgrounds (Lamming et al., 2013).”
BackgroundA novel rapamycin analog is highly selective for mTORC1 in vivo
Schreiber, K. H., Arriola Apelo, S. I., Yu, D., Brinkman, J. A., Velarde, M. C., Syed, F. A., Liao, C.-Y., Baar, E. L., Carbajal, K. A., Sherman, D. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11174-0 · Cited by 177
Self-citationProtein synthesis and quality control in aging
Anisimova, A. S., Alexandrov, A. I., Makarova, N. E., Gladyshev, V. N., & Dmitriev, S. E. (2018) · Aging · doi:10.18632/aging.101721 · Cited by 172
“Compounds that robustly expand the lifespan of many model organisms, rapamycin and its analogs (“rapalogs”) [112–115], affect translation via the mTORC1 signaling pathway [116,117].”
BackgroundGaubitz, C., Prouteau, M., Kusmider, B., & Loewith, R. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.04.001 · Cited by 164
“Indeed, some of the undesirable side effects of prolonged rapamycin treatment, including impaired sugar metabolism, are attributed to inhibition of MTORC2, although these might be mitigated with optimized treatment regimens [104,105].”
BackgroundShort‐term rapamycin treatment increases ovarian lifespan in young and middle‐aged female mice
Dou, X., Sun, Y., Li, J., Zhang, J., Hao, D., Liu, W., Wu, R., Kong, F., Peng, X., & Li, J. (2017) · Aging Cell · doi:10.1111/acel.12617 · Cited by 157
“Chronic, low-grade inflammation is a feature of aging, and a reduction in inflammation is proposed to be one of the mechanisms by which Rapa promotes longevity and healthspan (Lamming et al., 2013).”
BackgroundCalorie restriction mimetics: Can you have your cake and eat it, too?
Ingram, D. K., & Roth, G. S. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.11.005 · Cited by 161
Age-Related Impairment of Pancreatic Beta-Cell Function: Pathophysiological and Cellular Mechanisms
De Tata, V. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00138 · Cited by 142
“Metformin was also shown to increase longevity in species ranging from yeast to mice (145).”
BackgroundDai, S., Chen, T., Li, X., Yue, K., Luo, P., Yang, L., Zhu, J., Wang, Y., Fei, Z., & Jiang, X. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.005 · Cited by 161
“There are mTOR inhibitors already in clinical trials or that have been approved for the treatment of diseases associated with autophagy defects [50,51].”
BackgroundJoseph, G. A., Wang, S. X., Jacobs, C. E., Zhou, W., Kimble, G. C., Tse, H. W., Eash, J. K., Shavlakadze, T., & Glass, D. J. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00141-19 · Cited by 158
mTORC1 pathway in DNA damage response
Ma, Y., Vassetzky, Y., & Dokudovskaya, S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.06.011 · Cited by 154
Strategies for Achieving Healthy Vascular Aging
Nowak, K. L., Rossman, M. J., Chonchol, M., & Seals, D. R. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10439 · Cited by 151
“logs of rapamycin (rapalogs) are being developed as alternate therapies.(159)”
Cohen, R. A., Marsiske, M., & Smith, G. E. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00010-8 · Cited by 178
Anti-aging pharmacology: Promises and pitfalls
Vaiserman, A. M., Lushchak, O. V., & Koliada, A. K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.08.004 · Cited by 151
“These effects included metabolic abnormalities such as decreased insulin sensitivity, glucose intolerance, hyperlipidemia, hypertension, and enhanced incidence of new-onset diabetes (Lamming et al., 2013), as well as anaemia, diarrhoea, skin rash, thrombocytopenia, stomatitis, and malignancies (lymphoma and skin cance…”
BackgroundInfluentialAging and the emerging role of cellular senescence in osteoarthritis
Diekman, B. O., & Loeser, R. F. (2023) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2023.11.018 · Cited by 150
Signaling pathways in the development of infantile hemangioma
Ji, Y., Chen, S., Li, K., Li, L., Xu, C., & Xiang, B. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-13 · Cited by 145
“The overactivation of the PI3K/Akt/mTOR pathway, a signaling pathway that plays a key role in cellular growth and survival, has been implicated in various tumor pathogeneses, and as such, the inhibition of the PI3K/Akt/mTOR pathway is of therapeutic interest [112-114].”
BackgroundStrategies and Challenges in Clinical Trials Targeting Human Aging
Newman, J. C., Milman, S., Hashmi, S. K., Austad, S. N., Kirkland, J. L., Halter, J. B., & Barzilai, N. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw149 · Cited by 138
“Rapamycin extends life span in yeast, flies, and worms, as well as in C57BL/6, 129/Sv, and genetically heterogeneous mice, even when started late in life (see the recent reviews (65,66) for additional references) Rapamycin has a variety of effects in mice that might contribute to longevity, including modulating stem c…”
BackgroundHartman, N. W., Lin, T. V., Zhang, L., Paquelet, G. E., Feliciano, D. M., & Bordey, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.017 · Cited by 139
Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice
Arriola Apelo, S. I., Pumper, C. P., Baar, E. L., Cummings, N. E., & Lamming, D. W. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw064 · Cited by 138
“The discovery that continuous rapamycin treatment extends the life span of model organisms, including mice, has spurred significant interest in understanding the mechanistic basis for this effect as a means to avoid the many negative side effects associated with rapamycin in humans (12,14).”
BackgroundSelf-citationTargeting the mTOR Signaling Network for Alzheimer’s Disease Therapy
Wang, C., Yu, J., Miao, D., Wu, Z., Tan, M., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8505-8 · Cited by 142
“Firstly, rapamycin treatment has been observed to delay aging in evolutionarily diver organisms including mammalian [142].”
BackgroundRole of the inflammation-autophagy-senescence integrative network in osteoarthritis
Vinatier, C., Domínguez, E., Guicheux, J., & Caramés, B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00706 · Cited by 135
Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic
Moskalev, A., Chernyagina, E., Tsvetkov, V., Fedintsev, A., Shaposhnikov, M., Krut'ko, V., Zhavoronkov, A., & Kennedy, B. K. (2016) · Aging Cell · doi:10.1111/acel.12463 · Cited by 121
“protects against age-related diseases, including cardiac and neurodegenerative syndromes, as well as neoplasms (Johnson et al., 2013; Lamming et al., 2013).”
BackgroundThe metabolic syndrome and neuropathy: Therapeutic challenges and opportunities
Callaghan, B., & Feldman, E. (2013) · Annals of Neurology · doi:10.1002/ana.23986 · Cited by 126
“57 Interestingly, the type 2 diabetes drug metformin functions by activating adenosine monophosphate–activated protein kinase, which in turn negatively regulates mTOR signaling, and indirect mTOR regulatory mechanisms of metformin have also been recently uncovered.(56,58,59) Attention to chemokines as a therapeutic ta…”
BackgroundHurez, V., Dao, V., Liu, A., Pandeswara, S., Gelfond, J., Sun, L., Bergman, M., Orihuela, C. J., Galvan, V., Padrón, Á., et al. (2015) · Aging Cell · doi:10.1111/acel.12380 · Cited by 128
“However, it was developed as an immunosuppressive agent (Hasty et al., 2014), raising legitimate safety concerns (Lamming et al., 2013).”
BackgroundDrugs that modulate aging: the promising yet difficult path ahead
Kennedy, B. K., & Pennypacker, J. K. (2014) · Translational research · doi:10.1016/j.trsl.2013.11.007 · Cited by 127
“significant, the class of drugs has been approved for several disease indications (61, 62).”
BackgroundLv, Y., Yang, Y., Sui, B., Hu, C., Zhao, P., Liao, L., Chen, J., Zhang, L., Yang, T.-T., Zhang, S., et al. (2018) · Theranostics · doi:10.7150/thno.23620 · Cited by 128
“Further complicating matters, certain anti-aging pharmacology may exert detrimental side effects, such as the well-known immunosuppression by rapamycin [115, 116], in spite of its efficacy to improve MSC function in vivo [117, 118].”
BackgroundInsulin decreases autophagy and leads to cartilage degradation
Ribeiro, M. P., de Figueroa, P. L., Blanco, F. J., Mendes, A. F., & Caramés, B. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.10.017 · Cited by 131
Overnutrition, mTOR signaling, and cardiovascular diseases
Jia, G., Aroor, A. R., Martinez-Lemus, L. A., & Sowers, J. R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00262.2014 · Cited by 122
“Rapamycin is an FDA-approved drug for coating coronary stents, treating renal cancer, and suppression of immune response following transplant surgery (36).”
Liu, Y., Weng, W., Gao, R., & Liu, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4598167 · Cited by 129
“Experimental studies have also shown that by inhibiting the mTOR signaling pathway through gene knockout, rapamycin or dietary restriction can delay aging of various biological models, including yeast, worms, fruit flies, and mice [119].”
Background(2024) · doi:10.1016/j.cmet.2024.01.015 · Cited by 119
Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012518 · Cited by 119
“There is particular interest in finding less toxic analogs of rapamycin with improved pharmacokinetics (rapalogs), because rapamycin extends life span in mammals by targeting cellular senescence and autophagy (Wilkinson et al., 2012; Lamming et al., 2013).”
BackgroundAspirin Recapitulates Features of Caloric Restriction
Pietrocola, F., Castoldi, F., Markaki, M., Lachkar, S., Chen, G., Enot, D. P., Durand, S., Bossut, N., Tong, M., Malik, S. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.024 · Cited by 111
“Thus,mTORC1 inhibition by rapalogs (Lamming et al., 2013), activation of sirtuin-1 (SIRT1) with resveratrol (Wood et al., 2004), and supplementation of the natural polyamine spermidine (Eisenberg et al., 2009) extend lifespan in various model organisms in an autophagy-dependent manner (López-Otı́n…”
BackgroundFujitsuka, N., Asakawa, A., Morinaga, A., Amitani, M. S., Amitani, H., Katsuura, G., Sawada, Y., Sudo, Y., Uezono, Y., Mochiki, E., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.220 · Cited by 114
MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB
Hsu, C. L., Lee, E. X., Gordon, K. L., Paz, E. A., Shen, W.-C., Ohnishi, K., Meisenhelder, J., Hunter, T., & La Spada, A. R. (2018) · Nature Communications · doi:10.1038/s41467-018-03340-7 · Cited by 105
Mitani, A., Ito, K., Vuppusetty, C., Barnes, P. J., & Mercado, N. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0593oc · Cited by 116
“The mTOR inhibitor rapamycin has been considered a potential antiaging molecule (21).”
BackgroundPotential therapeutic effects of mTOR inhibition in atherosclerosis
Kurdi, A., De Meyer, G. R. Y., & Martinet, W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12820 · Cited by 108
Rapamycin directly activates lysosomal mucolipin TRP channels independent of mTOR
Zhang, X., Chen, W., Gao, Q., Yang, J., Yan, X., Zhao, H., Su, L., Yang, M., Gao, C., Yao, Y., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000252 · Cited by 115
“More recently, Rap was also shown to extend life span across diverse organisms ranging from flies to mammals [4, 5].”
BackgroundThe Target of Rapamycin Signalling Pathway in Ageing and Lifespan Regulation
Bjedov, I., & Rallis, C. (2020) · Genes · doi:10.3390/genes11091043 · Cited by 104
“The complexity and breadth of connections of mTOR signalling pathway with other nutrient- and growth factor-responsive pathways imposes great toxicity risks when using high doses of inhibitors [5,185] and optimal dosages and durations of treatment are unknown factors [186].”
BackgroundAdult Stem Cells and Diseases of Aging
Boyette, L., & Tuan, R. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3010088 · Cited by 108
“Rapamycin is unlikely to be utilized extensively as an anti-aging therapeutic due to its side effects, which include hyperlipidemia and immunosuppression; however, newer analogs of rapamycin (rapalogs) are in development and may find use as anti-aging compounds, along with other agents that inhibit mTOR (reviewed in […”
BackgroundTranscription errors induce proteotoxic stress and shorten cellular lifespan
Vermulst, M., Denney, A. S., Lang, M. J., Hung, C.-W., Moore, S., Moseley, M. A., Thompson, J. W., Madden, V. J., Gauer, J. W., Wolfe, K. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9065 · Cited by 117
Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis
Nassif, M., Valenzuela, V., Rojas-Rivera, D., Vidal, R., Matus, S., Castillo, K., Fuentealba, Y., Kroemer, G., Levine, B., & Hetz, C. (2014) · Autophagy · doi:10.4161/auto.28784 · Cited by 100
“Besides, it is well known that most of the drugs tested to stimulate autophagy have many other cellular targets.(90) Our current study using Becn1 heterozygous mice is the first direct demonstration for the possible involvement of autophagy on ALS, providing unexpected results.”
BackgroundTranscriptional regulation of the stress response by mTOR
Aramburu, J., Ortells, M. C., Tejedor, S., Buxadé, M., & López-Rodríguez, C. (2014) · Science Signaling · doi:10.1126/scisignal.2005326 · Cited by 99
“The precise mechanisms underlying the longevity phenotype in mice with reduced mTOR activity are still being elucidated, but it is already apparent that some processes benefit more than others from lower mTOR activity (168).”
BackgroundATAD3 proteins: brokers of a mitochondria–endoplasmic reticulum connection in mammalian cells
Baudier, J. (2018) · Biological Reviews · doi:10.1111/brv.12373 · Cited by 99
“Studies also described the involvement of ATAD3 and TOR in the C. elegans lifespan (Hoffmann et al., 2012; Lamming et al., 2013).”
Background
Metadata
- Authors
- Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Broad Institute (US)
- Corresponding author
- Baur, Joseph A.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 3
- Pages
- 980-989
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582126
- OpenAlex
- W2129902630
- Cited by
- 531
- References
- 133
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 42 · 2023: 37 · 2022: 41 · 2021: 25 · 2020: 28 · 2019: 44 · 2018: 46 · 2017: 38 · 2016: 57 · 2015: 61 · 2014: 46 · 2013: 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- American Federation for Aging Research
- American Heart Association
- Charles A. King Trust
- Starr Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health
- National Institute on Aging (K99AG041765)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, rapalogs, mTOR inhibitors, anti-aging therapeutics, longevity, lifespan extension, mTOR signaling, genetically heterogeneous mice, adverse drug reactions
- MeSH terms
- Aging, Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Autophagy, Humans, Metformin, Neoplasms, Stem Cells, Sirolimus, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.